Viralytics Limited (ASX:VLA) has expanded its cancer treatment patent portfolio after a notice of allowance of an additional patent by the US Patent and Trademark Office.
The use of Viralytics' lead product CAVATAK™ is already protected with a portfolio of patents across major world markets, for a number of Group A Coxsackie viruses, which are specific forms of the common cold virus.
This core portfolio covers the use of selected Coxsackie A viruses.
The additional patent in the US broadens patent protection across all Coxsackie A viruses and the wider Group C human enteroviruses that attach to intercellular adhesion molecule-1 in the process of targeting and destroying cancer cells.
CAVATAK™ is injected directly into cancer tumours, and acts to kill both local and metastatic cancer cells by direct cytolysis and a possible immune response.
A notice of allowance indicates the intention to grant a patent after an administrative process is completed.
The United States is the world’s largest pharmaceutical market and broadening patent protection in this market is valuable to Viralytics.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.